Medicare GLP-1 Bridge Offers $50 Weight-Loss Drugs for Eligible Part D Enrollees

Eligible Medicare Part D enrollees can now use the Medicare GLP-1 Bridge to access certain weight-loss GLP-1 drugs for a $50 monthly copay. The practical benefit is a predictable lower-cost route for some beneficiaries who meet the program's clinical rules, but it is not automatic and not every Medicare member will qualify.

The Centers for Medicare & Medicaid Services launched the short-term demonstration on July 1, 2026, and says it will run through December 31, 2027. For households trying to understand whether the program helps them, the first step is not price shopping; it is checking Part D coverage, eligibility criteria and prior authorization with a clinician.

What Changed on July 1

CMS said eligible Medicare beneficiaries may now get certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge. The agency describes the program as a short-term demonstration meant to expand access to selected GLP-1 drugs for weight management while testing how increased access affects Medicare.

CMS says the Bridge operates outside the normal Part D payment flow. That means Part D plan sponsors do not have to opt in for eligible beneficiaries to use the program, and CMS will use a central processor in 2026 to manage prior authorization, claims adjudication and pharmacy payment.

The program is temporary. CMS says it will operate from July 1, 2026, through December 31, 2027, after the agency delayed the Medicare Part D portion of the broader BALANCE model and extended the Bridge through 2027.

Who Should Check Eligibility First

Medicare.gov says the program is available nationwide to certain people with Medicare drug coverage, including standalone Part D plans, Medicare Advantage plans with drug coverage, Special Needs Plans, employer or union group waiver plans, and the Limited Income Newly Eligible Transition program.

The clinical gate is narrower. Medicare.gov says a beneficiary must be 18 or older and meet one of several BMI-and-condition tests: BMI of 35 or more; BMI of 30 to 34.99 with conditions such as diastolic heart failure, uncontrolled high blood pressure, stage 3a or higher chronic kidney disease, prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease; or BMI of 27 to 29.99 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease.

A provider still has to be involved. Medicare.gov says the doctor or other health care provider must send the prescription to the pharmacy and, when requested, complete prior authorization. The provider must also certify that the drug is being used as part of a lifestyle program focused on diet and exercise.

The $50 Copay Has Important Limits

The most useful number is also the easiest to misunderstand. CMS says eligible beneficiaries will have a $50 copay for drugs furnished under the Bridge, and Medicare's beneficiary publication says that cost applies no matter the person's income level.

But the $50 payment does not behave like ordinary Part D cost sharing. CMS says the Part D deductible does not apply, the copay does not count toward the beneficiary's true out-of-pocket costs, and low-income subsidy help is not provided for low-income subsidy beneficiaries. Medicare's publication also says the drugs are not eligible for the Medicare Prescription Payment Plan.

That is the second-layer budget lesson: a lower sticker price can still be hard to carry if it sits outside the usual protections. KFF notes that the $50 copay will not count toward the Part D deductible or the 2026 out-of-pocket maximum and that the lack of low-income subsidy support could make the program harder for some low- and modest-income beneficiaries to use.

Which Drugs Are Covered

Medicare.gov lists three covered options for the Bridge: Foundayo as a tablet, Wegovy as an injection or tablet, and Zepbound KwikPen only. The page says the program does not cover single-dose Zepbound vials or pens.

The exclusions matter for people already taking a GLP-1. Medicare's beneficiary publication says a person is not eligible if they have been using a GLP-1 paid for by a Medicare drug plan for any reason and need to keep getting that GLP-1 through the plan. Medicare.gov also says people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible through the Bridge, though their Part D plan might cover GLP-1s for those conditions.

What to Watch Before Starting

The first checkpoint is whether the pharmacy and provider can actually process the Bridge path. CMS says it has released resources for prescribers and pharmacies, and Medicare.gov says prior authorization is valid through December 31, 2027, unless the beneficiary changes GLP-1s.

The second checkpoint is medical fit, not just affordability. El Pais US reported that older adults may need careful monitoring because weight-loss treatment can involve muscle loss, bone-density concerns and demand for clinical follow-up. The article should not be read as medical advice; the practical financial decision still belongs in a conversation with a qualified clinician.

The final checkpoint is what happens after 2027. KFF says it is uncertain how participating beneficiaries will maintain Medicare coverage for GLP-1 medication for obesity after the Bridge ends, pending future CMS action on the broader Medicare Part D model. That makes the program useful now, but not yet a permanent coverage guarantee.

FAQ

Does every Medicare beneficiary qualify for the $50 GLP-1 copay?

No. CMS and Medicare.gov both say the Bridge is for eligible beneficiaries with Medicare drug coverage who meet specific clinical and authorization requirements. People who already receive GLP-1 coverage through Part D, or who qualify for GLP-1 coverage through Part D for certain covered conditions, are not eligible through the Bridge route.

Does the $50 copay count toward the Part D out-of-pocket limit?

No. CMS says the $50 copay does not count toward true out-of-pocket costs, and Medicare's beneficiary publication says it does not count toward the Medicare drug plan deductible or yearly out-of-pocket limit.

Where should beneficiaries check first?

CMS points beneficiaries to Medicare.gov/glp1bridge and 1-800-MEDICARE for program information. Because prior authorization and clinical criteria are central to the program, beneficiaries should also talk with their doctor or other health care provider before assuming the $50 route applies.